Pharmaceuticals: Novo Nordisk's Wegovy Outlook StrongPharmaceutical giant Novo Nordisk (NVO) is poised for a significant milestone as its CEO confirms that FDA approval for the high-dose version of its popular weight-loss drug, Wegovy, remains on track for the first quarter of 2026. This comes on the heels of positive early signs from the high-dose Wegovy launch in the UK, suggesting strong international demand for the treatment. The anticipated approval could further solidify Novo Nordisk's position in the ...